VIDAZA® Treatment for MDSa

About MDS

Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological malignancies characterised by bone marrow dysplasia and peripheral cytopenias.1,2

Expand All

What is MDS?

MDS at a Glance

Typical Symptoms of MDS

Intermediate (Int)-2 and High-risk MDS are fatal haematological malignancies.


Annual incidence


Cytogenetics and MDS

Diagnosing MDS

MDS Classification Systems

Current Treatment Options for MDS

Evaluating responses to MDS treatment

  1. Malcovati L et al. J Clin Oncol 2005. 23: 7594-7603.
  2. Kurzrock R. Semin Hematol 2002. 39(Suppl 2): 18-25.
  3. Aul C et al. Leuk Lymphoma. 1995.16: 247-262.
  4. Ross SD et al. Oncologist. 2007. 12:1264-1273.
  5. Kouides PA, Bennett JM. Understanding myelodysplastic syndromes: a patient handbook. 3rd edition. Myelodysplastic Syndromes Foundation. 2004.
  6. Greenberg P, et al. Blood. 1997. 89: 2079-2088.
  7. List AF et al. Hematology Am Soc Hematol Educ Program 2004. 2004: 297-317.
  8. Fenaux P et al. Lancet Oncology 2009. 10:223-232.
  9. Rollison DE et al. Blood 2008. 112: 45-52.
  10. Bowen D. Br J Haematol 2003. 120: 187-200.
  11. Hamblin TJ. Epidemiology of MDS. In: Bennett JM (ed).MDS: Pathobiology and Clinical Management. New York:Marcel Dekker Inc. 2002.
  12. Giagounidis A. Haematologica Reports 2006. 2: 5-10.
  13. NCCN Guidelines on Myelodysplastic Syndromes V.2.2011.
  14. Bennett JM et al. Br J Haematol 1982. 51: 189-199.
  15. Greenberg P et al. Blood 1998. 91: 1100.
  16. List AF and Doll DC. Myelodysplastic syndromes. In: Wintrobeʼs clinical hematology, 2004.
  17. Cheson B et al. Blood 2000. 96: 3671-3674.
a. MDS-specific Indication

VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:

Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ?20% to <30% as AML patients.


This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.